Search

everythinglearnresearchcommunity

for

Search:↓

3D-printed hydrogels show promise in medicine but face challenges in resolution, cell viability, cost, and regulations.

Extracellular vesicles could help tailor drug treatments, but more research is needed.

3D bioprinting offers new ways to treat head and neck defects with bioinks that mimic natural tissues.

Induced pluripotent stem cells are a major breakthrough in regenerative medicine.

Paclitaxel is an effective cancer drug with side effects and potential new uses beyond cancer.

Hydrogel composites have great potential in regenerative medicine, tissue engineering, and drug delivery.

COVID-19 may harm male reproductive health and lower testosterone levels, potentially affecting fertility and causing erectile dysfunction. More research is needed.

Prostate cancer is common, but risk can be reduced by avoiding smoking, unhealthy diet, inactivity, certain medications, and risky jobs.

Prostate cancer cells can make their own androgens to activate the androgen receptor, and treatments like abiraterone may increase this ability, suggesting new therapies should target the entire steroid-making pathway.

Drugs that block DHT production can effectively treat enlarged prostate and improve urinary issues with some sexual side effects.

ERG increases SOX9, promoting prostate cancer growth and invasion.

Different animals have unique versions of the enzyme that changes testosterone into another hormone, which is important for creating effective treatments for prostate and hair loss conditions.

Prostate cancer was a major health issue in 2009, especially for Black men, and targeting the 5alpha-reductase enzyme could help in its prevention and treatment.

Researchers developed promising agents for prostate cancer imaging, with the best one showing high potential for clinical use.

Dutasteride and finasteride do not significantly affect bone density, blood fats, or blood production, but slightly lower PSA levels and minimally impact sexual function in healthy young men.

A protein called CBP is found in prostate cancer and can increase the effectiveness of certain prostate cancer treatments.

The guidelines aim to find treatable prostate cancer early while avoiding unnecessary tests and treatments.

Steroidogenesis inhibitors change but don't stop androgen production in prostate cancer.

The document suggests that targeting the hormone DHT could be a more effective treatment for prostate cancer than targeting testosterone.

Steroid sex hormones activate matriptase in prostate cancer cells but not in breast cancer cells.

Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.

Low androgen levels might delay prostate cancer but could lead to more aggressive, therapy-resistant cancers.

Finasteride might lower the risk of low-grade prostate cancer but not high-grade cancer, while alpha-blockers might reduce high-grade cancer risk.

5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.

Men who experienced baldness at age 20 may have double the risk of getting prostate cancer.

Finasteride reduces prostate cancer risk but may affect ejaculatory volume and requires careful consideration for young men.

Large prostate links to more hair loss, but age of onset doesn't affect it.

Men with benign prostatic hyperplasia are more likely to have metabolic syndrome than those without it.

SRD5A1 is crucial in advanced prostate cancer, and blocking both SRD5A1 and SRD5A2 is more effective than targeting SRD5A2 alone.

The study found no link between baldness patterns and androgen levels in men with benign prostate enlargement or prostate cancer.